UAE Approves AstraZeneca’s Baxfendy for Hypertension
AstraZeneca has received approval from the Emirates Drug Evaluation (EDE) in the UAE for Baxfendy, a novel treatment employing the active ingredient baxdrostat, aimed at addressing uncontrolled hypertension. This approval marks a significant milestone for AstraZeneca as it expands its portfolio in the cardiovascular space, reflecting the growing demand for innovative therapies to manage hypertension…









